4SA Stock Chart & Stats
€0.25
>-€0.01(-0.99%)
At close: 4:00 PM EDT
€0.25
>-€0.01(-0.99%)
Day’s Range― - ―
52-Week Range€0.12 - €0.41
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.67M
Enterprise Value€70.31M
Total Cash (Recent Filing)€9.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding21,163,902
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€948.40K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth indicates that AcouSort is gaining commercial traction for its acoustofluidic solutions. If sustained, expanding sales can improve operating leverage, support broader customer adoption, and provide a stronger base for scaling the business over the next several quarters.
Debt-Free Balance SheetThe absence of reported debt reduces solvency and interest-cost pressure while preserving financial flexibility. A debt-free structure gives AcouSort more room to direct available resources toward product development, customer integration, and commercialization as it works toward profitability.
Broad Technology ApplicationsThe technology serves multiple life-science use cases, including cell therapy, diagnostics, and research. This application breadth can diversify potential customer demand and create several routes for module, system, and integration revenue as adoption of advanced cell handling expands.
Bears Say
Deeply Negative ProfitabilityNegative gross profit and substantial operating and net losses show that AcouSort has not yet established a stable, scalable profit model. Continued losses can restrict reinvestment capacity and make future performance dependent on meaningful margin improvement and stronger commercial execution.
Persistent Cash BurnOngoing negative operating and free cash flow indicates that current operations are consuming cash rather than funding growth internally. Until profitability improves, elevated cash requirements may constrain investment choices and increase reliance on external financing to sustain development and commercialization.
Shrinking Equity BaseThe sharp reduction in equity reflects the cumulative impact of ongoing losses and weak returns on capital. A smaller equity base reduces financial resilience and, if cash burn persists, increases the possibility that additional funding could dilute existing shareholders.
4SA FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was €0.12 and its highest was €0.41 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is €5.67M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Nov 25, 2026 which is in 45 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on Aug 26, 2026. The company reported -€0.015 earnings per share for the quarter.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -7.631%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in DE:4SA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.